Evaxion A/S is a clinical‐stage biotechnology company focused on harnessing artificial intelligence to develop novel immunotherapies. Headquartered in Copenhagen, Denmark, the company leverages its proprietary AI‐powered platforms to design precision vaccines and therapeutic candidates targeting both oncology and infectious diseases. Evaxion’s approach integrates computational algorithms with advanced immunology to accelerate the discovery and optimization of immunogenic peptides capable of triggering robust immune responses.
The company’s core offering is its PIONEER™ drug discovery platform, which utilizes machine learning and deep sequencing data to predict and validate epitopes that can be formulated into vaccines or biologics. Evaxion has built a diverse pipeline of preclinical and clinical‐stage products, including personalized cancer vaccines aimed at neoantigens in solid tumors and preventive vaccines for emerging infectious threats. By combining in silico design with in vitro and in vivo validation, Evaxion seeks to reduce development timelines and increase the likelihood of clinical success.
Founded in 2017 as a spin‐out from Danish academic institutions, Evaxion has grown to serve a global market, collaborating with leading research centers and pharmaceutical partners in Europe and the United States. The company’s research programs encompass areas such as melanoma, non‐small cell lung cancer, and neglected tropical diseases. Over time, Evaxion has secured strategic alliances to advance its clinical trials and expand manufacturing capabilities, positioning itself as an innovator in the field of AI‐driven immunotherapy.
Evaxion’s leadership team combines expertise in computational biology, immuno‐oncology, and pharmaceutical development. The executive management and scientific advisory board include seasoned professionals with backgrounds in biostatistics, molecular immunology, and regulatory affairs. Under this multidisciplinary leadership, Evaxion continues to refine its AI platforms and drive multiple collaborative programs toward clinical milestones, aiming to deliver first‐in‐class therapeutics that address critical unmet needs in cancer and infectious disease treatment.
AI Generated. May Contain Errors.
